Epizyme, Inc. (EPZM)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.70+0.16 (+2.12%)
At close: 4:00 PM EDT
People also watch:
OMEDXLRNAGIOENTAKPTI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close7.54
Bid6.90 x 300
Ask8.24 x 600
Day's Range7.48 - 7.85
52wk Range7.36 - 21.28
1y Target EstN/A
Market Cap446.27M
P/E Ratio (ttm)-3.92
Beta2.12
Volume251,957
Avg Vol (3m)389,742
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Epizyme Doses First Patient in Phase II Mesothelioma Study
    Zacks14 days ago

    Epizyme Doses First Patient in Phase II Mesothelioma Study

    Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.

  • Capital Cube18 days ago

    ETF’s with exposure to Epizyme, Inc. : August 11, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Epizyme, Inc. Here are 5 ETF’s with the largest exposure to EPZM-US. Comparing the performance and risk of Epizyme, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire18 days ago

    Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma

    CAMBRIDGE, Mass., Aug. 11, 2016-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company’ s ...